leadf
logo-loader
viewBristol-Myers Squibb Co

Bristol-Myers Squibb shares fall after FDA delays approval for lung cancer therapy

The EU is also requesting more information on overall survival rates for patients in the study

Medical workers.
Bristol-Myers Squibb is a global biopharmaceutical company.

Bristol-Myers Squibb Company (NYSE:BMY) stock slumped Monday after the US Food and Drug Administration delayed for three months, until May 2019, a decision on its combination drug treatment for lung cancer.

In a statement, Bristol-Myers said new data submitted by the company was viewed by the FDA as a major amendment to its drug application and extended its PDUFA date to May 20, 2019. The new information that Bristol-Myers submitted to the FDA is about the overall survival for patients whose tumors have a relatively low level of mutations.

The trial in the US is called CheckMate-227. It is an ongoing Phase 3 study of Opdivo plus another dose of a Bristo-Myers drug, Yervoy, against chemotherapy in small cell lung cancer.

As part of the ongoing EU review process, the Committee for Medicinal Products for Human Use (CHMP) requested additional information, including an overall survival (OS) analysis of Opdivo plus Yervoy in patients.

READ: Bristol-Myers Squibb's 2Q earnings beat Street on healthy sales of its blockbuster cancer drug Opdivo

The impact on Bristol shares was negative. 

Bristol-Myers stock retreated 5.5% to $51.27, trading between $50.51 and $51.90.

Opdivo harnesses the body’s own immune system to fight cancer, having become an important treatment option across multiple cancers. 

Bristol-Myers Squibb is a global biopharmaceutical company which tries to develop and deliver medicines that help patients over serious diseases.

The company is based in Princeton, New Jersey.

Reporting by Rene Pastor, contactable on rene.pastor@proactiveinvestors.com

Quick facts: Bristol-Myers Squibb Co

Price: 60.67 USD

NYSE:BMY
Market: NYSE
Market Cap: $136.9 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Melkior Resources signs earn in deal with Kirkland Lake Gold as they look to...

Melkior Resources (CVE: MKR-OTC: MKRIF) CEO Jonathon Deluce joined Steve Darling from Proactive Vancouver with news the company has announced a strategic partnership with Kirkland Lake Gold. Deluce telling Proactive about the deal and why Kirkland Lake was such a good fit. Deluce also shared...

1 hour, 53 minutes ago

2 min read